Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Voyager Therapeutics excels in 2022, poised for CNS therapeutic breakthroughs

Voyager Therapeutics demonstrated strong performance in 2022, leveraging key partnerships and advancements in their pipeline programs to drive innovation and growth in the CNS therapeutics space.
While facing challenges in operational clarity and regulatory hurdles, the company's scientific strengths and financial stability position it well to capitalize on opportunities for expanding collaborations and advancing novel therapeutic approaches.
With a focus on CNS delivery, tissue targeting, and surrogate markers, Voyager is poised to make significant strides in addressing neurological disorders and enhancing treatment efficacy, offering potential value for investors and patients alike.

Voyager Therapeutics reports strong Q1 earnings and strategic advancements

Voyager Therapeutics showcased robust financial performance and strategic advancements in neurotherapeutics and gene therapy, positioning the company for future growth.
While facing challenges related to animal model predictability and reimbursement considerations, Voyager is actively leveraging strengths in diversified therapeutic approaches and strategic partnerships.
Opportunities lie in exploring synergistic treatments, proactive risk mitigation, and innovative therapeutic strategies to address complex neurological disorders effectively.
Overall, Voyager's focus on innovation, strategic partnerships, and comprehensive drug development approaches underscores its commitment to advancing treatments for neurological diseases.

Voyager Therapeutics excels in Q2, poised for neurogenetic medicine expansion

Voyager Therapeutics demonstrated strong financial health, innovative advancements in CNS programs, and strategic partnerships driving revenue growth. While facing challenges in R&D management and program milestones, the company's opportunities lie in upcoming milestones and expansion in neurogenetic medicine.

Voyager Therapeutics advances CNS gene therapy with strong partnerships and cash balance

Voyager Therapeutics is making strides in CNS gene therapy delivery with strong financial backing
Facing challenges in toxicology studies and patient recruitment while eyeing collaboration opportunities
Opportunities lie in biomarker utilization, partnership models, and advancing key programs towards clinical milestones

Voyager Therapeutics reports robust earnings and advances in neurogenetic therapies

Voyager Therapeutics showcased a strong financial performance, progress in their pipeline programs, and a focus on innovation and differentiation in the gene therapy space.
While facing competition and regulatory challenges, the company's strategic strengths, collaborations, and positive data present opportunities for future growth and impact.
Analysts' inquiries into program progress and regulatory timelines underscore investor interest in Voyager's development trajectory and the potential of their neurogenetic therapies.
With a robust financial position, promising pipeline advancements, and a commitment to unique approaches, Voyager is poised to make significant strides in the treatment of neurological disorders.

Voyager Therapeutics excels in Q1, eyes Alzheimer's breakthroughs

Voyager Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2024.
The company's focus on neurogenetic medicine and innovative gene therapy programs is a key strength.
Challenges include demonstrating efficacy in ALS therapy and optimizing brain delivery methods.
Opportunities lie in exploring novel treatment approaches and anticipating key data releases.

Voyager Therapeutics excels in Q2 with innovative pipeline advancements

Voyager Therapeutics demonstrated strong performance in Q2 2024, focusing on key milestones, tau-directed programs, and derisking strategies.
While facing challenges in program optimization and competitive positioning, the company's strengths lie in innovative pipeline advancements and financial stability.
Opportunities for multi-organ specificity, disease-specific programs, and treatment refinement position Voyager for continued growth and therapeutic innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Compania de Minas Buenaventura

Ecopetrol

Skechers U.S.A.

Western Union

EC, SKX, BVN, VYGR and WU have been added to the Zacks Rank #1 (Strong Buy) List on May 1, 2023.

New Strong Buy Stocks for May 1st

Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer's disease and ALS Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer's disease and ALS

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson's disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager's TRACER™ capsid discovery platform. The companies expect to file an Investigational New Drug (IND) application with the FDA for the program in 2025.

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

AMN Healthcare Services

Bristol-Myers

CVS Health

Patterson Companies

Royalty Pharma

Semler Scientific

With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

VAALCO Energy

Galiano Gold

Hudson Technologies

iQIYI

Lincoln Educational Services

TransAlta

If soaring consumer prices got you down, you may want to consider these value stocks under $20. Sure, the market may be booming during this unique post-pandemic cycle.

Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20

The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis. Despite the risks and uncertainties, long-term investors may be rewarded once the company's products reach clinical trial validation. Voyager's investors should expect share price volatility. Nonetheless, based on my financial valuation and the potential upsides, I consider this company as a “buy”.

Voyager Therapeutics: On Track To Deliver High Returns On Investment

Voyager Therapeutics Inc (NASDAQ:VYGR) announced that it has executed a royalty agreement with its carbon capture and drug development partner Rain Cage Carbon. The royalty agreement has solidified the exclusive development and license agreement between the two companies, Voyageur said.

Voyageur Therapeutics executes royalty agreement with Rain Cage Carbon

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc.

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcript

- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering -

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Arcturus Therapeutics

Incyte

Jazz Pharmaceuticals

Ocuphire Pharma

United Therapeutics

Veracyte

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich's ataxia (FA) program. The candidate combines a frataxin (FXN) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager's TRACER™ capsid discovery platform. The companies expect the program to advance into first-in-human clinical trials in 2025.

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

- Additional new data demonstrate VY-TAU01, Voyager's lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) -

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on February 14, 2024, at 11:20 a.m. ET.

Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference

Ardmore Shipping

Canadian Solar

The financial markets in 2024 will be pulsating with transformative opportunities driven by companies poised to redefine industries. This is leading to several 2024 investment trends making themselves known, and several stocks gaining traction.

Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024

Novartis

Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with Novartis AG NYSE: NVS.

Voyager Therapeutics stock pops 30% on deal with Novartis

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who so choose in lieu of common stock, pre-funded warrants to purchase an aggregate of 3,333,333 shares of common stock at a public offering price of $8.999 per pre-funded warrant, for aggregate gross proceeds of approximately $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The purchase price per pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of each pre-funded warrant. All of the securities in the offering are being sold by the Company. The offering is expected to close on or about January 9, 2024, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,666,665 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Voyager Therapeutics Announces Pricing of Public Offering

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) --  Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the securities in the proposed offering are to be sold by the Company. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $15 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Voyager Therapeutics Announces Proposed Public Offering

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024, at 9:45 a.m. PT (12:45 p.m. ET).

Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Voyager Therapeutics' announcement that it has entered into an additional up to $1.2 billion collaboration with Novartis AG (ADR) (NYSE:NVS) for its TRACER capsids to develop potential gene therapies for Huntington's disease and spinal muscular atrophy has Baird analysts positive on Voyager's long-term outlook. “Moving forward, we continue to be encouraged by high level of partnership interest in TRACER and maintain positive on Voyager shares as we look ahead to what are likely to be transformative years for the company,” the analysts wrote in a note to clients.

Voyager Therapeutics' Novartis deal has analysts bullish on stock's long-term outlook

Shares of Voyager Therapeutics Inc. (VYGR) jumped Tuesday after the biotech firm agreed to a strategic collaboration and capsid licensing agreement with Novartis AG (NVS) to treat neurological illnesses.

Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments

Voyager Therapeutics (NASDAQ: VYGR ) stock is up by more than 25% today after the company agreed to a licensing deal with Novartis (NYSE: NVS ). Novartis will pay $100 million upfront in a “target-exclusive license” for Voyager's RNA-based screening platform and access to a Huntington's Disease treatment that is in pre-clinical trials.

News for Voyager Therapeutics Stock (VYGR)